Teva Rises to Five-Month High on U.S.-Traded Shares Advance
Teva Pharmaceutical Industries Ltd. (TEVA), the world’s largest maker of generic drugs, climbed to the highest level in almost five months following an increase in its U.S.-traded stock.
The shares in the Petach-Tikva, Israel-based company rose to the highest level since July 20, gaining 2.8 percent to 162.90 shekels, or the equivalent of $42.89, at the 4:30 p.m. close in Tel Aviv. Teva’s U.S.-traded shares closed at $42.72 on Dec. 16.
Teva has declined 12 percent in Tel Aviv this year.
To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at firstname.lastname@example.org
To contact the editor responsible for this story: Claudia Maedler at email@example.com
Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.